On July 19, 2025, in Hanoi, the VNUHCM-US Stem Cell Institute (SCI) and Hòa Lạc Stem Cell Technology Joint Stock Company (Hòa Lạc Stem Cell – HSC) officially signed a Memorandum of Understanding (MoU), marking an important step forward in scientific and technological cooperation between the two parties. Vision for Collaboration
The two sides commit to establishing a sustainable, strategic partnership aimed at:
- Enhancing community health care quality through high-tech medical services.
- Promoting regenerative medicine by applying stem cells and immune cells in clinical treatment.
- Standardizing procedures according to international standards (ISCT, AABB, FACT) and Vietnamese law.
Key Areas of Collaboration
Under the agreement, the two parties will focus on five domains:
- Advanced Training: SCI will transfer technologies for stem cell / immune cell isolation, culture, and preservation to the HSC staff.
- Technical Transfer: Deploy advanced, internationally-compliant processes from collection to clinical application.
- Quality Monitoring: Establish internal control systems aiming for international certification.
- Joint Research: Collaborate on scientific projects and expand treatment scopes.
- Parallel Communication: Raise public awareness of regenerative medicine.
Participating in the signing ceremony, the SCI was represented by Assoc. Prof. Pham Van Phuc (Director); and HSC by Mr. Phan Tú Quân (CEO).
During the event, Assoc. Prof. Pham Van Phuc delivered a presentation on “Stem Cell Economics & Business,” providing attendees with an overview of current economic and business trends in the stem cell industry.
Leave a Reply